Evidence map›Paper›PMID 33458891›Full record

ReviewJournal of internal medicine2021

Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer's disease (MCI and dementia) in primary care: a review and synthesis.

J L Liss, S Seleri Assunção, J Cummings, A Atri, D S Geldmacher, S F Candela, D P Devanand, H M Fillit, J Susman, J Mintzer and 11 more

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06601933 (Cognitive Training and Neuroplasticity in Mild Cognitive Impairment), which is not on this map. Cited by 151 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
151citing papers in PubMed, 7 pooled it
26.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06601933 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

Cognitive Training and Neuroplasticity in Mild Cognitive Impairment: COGIT-2 Trial

TypeinterventionalSponsorColumbia UniversityRan2024 to 2030Enrolled240ConditionsMild Cognitive Impairment (MCI), Cognitive TrainingArmsCognitive Training
3 · Its place in the literature

Who cites it

151 citing papers in PubMed, 7 syntheses or guidelines pooled it, 293 citations in OpenAlex.

  1. Pooled it
  2. Cost-effectiveness of testing biofluid biomarkers to diagnose Alzheimer's disease: a systematic review.The European journal of health economics : HEPAC : health economics in prevention and care · 2026
    Pooled it
  3. Guideline
  4. Pooled it
  5. Palliative Care in Early Dementia.Journal of pain and symptom management · 2024
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

91 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 18 institutions in 2 countries.

J L LissFrom, The Columbus Memory Center, Columbus, GA, USA.
S Seleri AssunçãoUS Medical Affairs - Neuroscience, Genentech, A Member of the Roche Group, South San Francisco, CA, USA.
J CummingsChambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada, Las Vegas, NV, USA.
A AtriBanner Sun Health Research Institute, Sun City, AZ, USA.
D S GeldmacherDepartment of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
S F CandelaHealth & Wellness Partners, LLC, Upper Saddle River, NJ, USA.
D P DevanandDivision of Geriatric Psychiatry, New York State Psychiatric Institute and Columbia University Irving Medical Center, New York, NY, USA.
H M FillitDepartments of Geriatric Medicine, Medicine, and Neuroscience, Icahn School of Medicine and Mt. Sinai, New York, NY, USA.
J SusmanDepartment of Family and Community Medicine, Northeast Ohio Medical University, Rootstown, OH, USA.
J MintzerRoper St Francis Healthcare, Charleston, SC, USA.
T BittnerF.Hoffmann-LaRoche, Basel, Switzerland.
S A BruntonDepartment of Family Medicine, Touro University, Vallejo, CA, USA.
D R KerwinKerwin Medical Center, Dallas, TX, USA.
W C JacksonDepartments of Family Medicine and Psychiatry, University of Tennessee College of Medicine, Memphis, TN, USA.
G W SmallDivision of Geriatric Psychiatry, UCLA Longevity Center, Semel Institute for Neuroscience & Human Behavior, University of California - Los Angeles, Los Angeles, CA, USA.
G T GrossbergDivision of Geriatric Psychiatry, St Louis University School of Medicine, St Louis, MO, USA.
C K ClevengerDepartment of Neurology, Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA, USA.
V CotterJohns Hopkins School of Nursing, Baltimore, MD, USA.
R StefanacciJefferson College of Population Health, Thomas Jefferson University, Philadelphia, PA, USA.
A Wise-BrownUS Medical Affairs - Neuroscience, Genentech, A Member of the Roche Group, South San Francisco, CA, USA.
M N SabbaghLou Ruvo Center for Brain Health - Cleveland Clinic Nevada, Las Vegas, NV, USA.ORCID 0000-0002-0882-662X
Cleveland Clinic · USLa Roche College · USAlzheimer's Drug Discovery Foundation · USBrigham and Women's Hospital · USColumbia University Irving Medical Center · USColumbus Center · USEmory University · USJohns Hopkins University · USNortheast Ohio Medical University · USRalph H. Johnson VA Medical Center · USRoche (Switzerland) · CHSaint Louis University · USSt. Mary-Corwin Medical Center · USThomas Jefferson University · USTouro University California · USUniversity of Alabama at Birmingham · USUniversity of California, Los Angeles · USUniversity of Tennessee Health Science Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The critical role of primary care clinicians (PCCs) in Alzheimer's disease (AD) prevention, diagnosis and management must evolve as new treatment paradigms and disease-modifying therapies (DMTs) emerge. Our understanding of AD has grown substantially: no longer conceptualized as a late-in-life syndrome of cognitive and functional impairments, we now recognize that AD pathology builds silently for decades before cognitive impairment is detectable. Clinically, AD first manifests subtly as mild cognitive impairment (MCI) due to AD before progressing to dementia. Emerging optimism for improved outcomes in AD stems from a focus on preventive interventions in midlife and timely, biomarker-confirmed diagnosis at early signs of cognitive deficits (i.e. MCI due to AD and mild AD dementia). A timely AD diagnosis is particularly important for optimizing patient care and enabling the appropriate use of anticipated DMTs. An accelerating challenge for PCCs and AD specialists will be to respond to innovations in diagnostics and therapy for AD in a system that is not currently well positioned to do so. To overcome these challenges, PCCs and AD specialists must collaborate closely to navigate and optimize dynamically evolving AD care in the face of new opportunities. In the spirit of this collaboration, we summarize here some prominent and influential models that inform our current understanding of AD. We also advocate for timely and accurate (i.e. biomarker-defined) diagnosis of early AD. In doing so, we consider evolving issues related to prevention, detecting emerging cognitive impairment and the role of biomarkers in the clinic.

Indexed as

Primary Health CareAlzheimer DiseaseHumansTime FactorsAlzheimer diseasebiomarkersdementiadisease-modifying therapiesmild cognitive impairmentprimary health care

Identifiers

PMID33458891
PMCPMC8359937
OpenAlexW3125656453

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.